Home > List All Publishers > BioSeeker Group AB

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.
BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker Group clients and projects are kept confidential.

List of reports from BioSeeker Group AB

Analytical Tool - Colorectal Cancer 2/21/2012 \| published by: BioSeeker Group AB ... of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and ... \| more...	$4,650.00
Analytical Tool - Hematological Cancers 2/21/2012 \| published by: BioSeeker Group AB ... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ... \| more...	$8,925.00
Analytical Tool - Lymphoma 2/21/2012 \| published by: BioSeeker Group AB ... development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool ... \| more...	$4,650.00
Analytical Tool - Angiogenesis in Oncology 2/21/2012 \| published by: BioSeeker Group AB ... time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current ... \| more...	$4,650.00
Analytical Tool - Cancer Immunotherapy 2/21/2012 \| published by: BioSeeker Group AB ... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ... \| more...	$8,925.00
Analytical Tool - Cancer Vaccines 2/21/2012 \| published by: BioSeeker Group AB ... research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. ... \| more...	$4,650.00
Analytical Tool - Leukemia 2/21/2012 \| published by: BioSeeker Group AB ... research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. ... \| more...	$4,650.00
Analytical Tool - Lung Cancer 2/21/2012 \| published by: BioSeeker Group AB ... analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ ... \| more...	$4,650.00
Analytical Tool - Protein Kinase Inhibitors in Oncology 2/21/2012 \| published by: BioSeeker Group AB ... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ... \| more...	$5,325.00
Apoptosis in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... developing 229 apoptotic drugs in 1003 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 147 drugs. Apoptosis In ... \| more...	$2,249.00
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 166 companies plus partners developing 209 B cell receptor pathway targeting drugs in 690 developmental ... \| more...	$2,249.00
Brain Cancer Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are today 183 companies plus partners developing 186 ... \| more...	$2,249.00
Cancer Vaccines Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... are today 215 companies plus partners developing 241 cancer vaccine drugs in 499 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years ... \| more...	$2,249.00
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 239 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one ... \| more...	$2,249.00
FSH Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity of the p38 MAPK, ERK, and PI3K signaling cascades. FSH ... \| more...	$2,249.00
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... in 123 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Hedgehog Signaling Pathway In Oncology Drug ... \| more...	$749.00
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 104 drugs. Il-2 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress ... \| more...	$2,249.00
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 71 drugs. Il-3 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a ... \| more...	$2,249.00
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 129 drugs. Il-6 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a ... \| more...	$2,249.00
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 19 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one ... \| more...	$749.00
Immunotherapy in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... development into one source.There are today 469 companies plus partners developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer. In addition, there are 16 suspended drugs and the accumulated number of ceased drugs ... \| more...	$3,675.00
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... There are today 144 companies plus partners developing 203 Kit receptor pathway targeting drugs in 694 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over ... \| more...	$2,249.00
Liver Cancer Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... another 46 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 128 different targets. These targets are further categorized ... \| more...	$1,499.00
Lung Cancer Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of ... \| more...	$2,249.00
Melanoma Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... remains below 20%.There are today 238 companies plus partners developing 269 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount ... \| more...	$2,249.00

< prev 4 5 6 7 8 9 10 11 12 13 next >